The product, Basalog, is the first diabetic drug whose effect lasts a full 24 hours, Biocon chief Kiran Mazumdar-Shaw told reporters here.
The drug will be available in Indian market from Saturday in 10ml and 3ml vials.
Basalog is effective for both type one and type two diabetics, Mazumdar-Shaw said.
“Diabetes is a debilitating disease, affecting global population like a pandemic. Sadly India is the epicentre of the disease. Basalog is part of Biocon’s commitment to provide best of diabetes management and care in India,” she said.
“The prominent feature of Basalog is that it has 24-hour long peek less action, the first in the country. It ensures effective HbA1c control and has flexibility of injection timing, unlike other insulin,” added Mazumdar-Shaw.
HbA1c is a diagnostic test to ascertain the patient’s blood glucose level for a three-month period.
According to statistics, India has the largest diabetic population in the world with around 40 million people.
Currently, there would be around 200-230 million diabetics in the world.
“Biocon’s research efforts over the years have yielded many important bio-therapeutics for diabetes and other life threatening diseases. Basalog is truly a life changing drug for diabetes management that has an effect of 24-hour duration,” said Rakesh Bamzai, president-marketing of Biocon.
“The drug is also priced at an affordable rate for Indian patients,” he added.
The price of 10ml vial is Rs.2,500.
Filed under Insulin, News | Tags: Bangalore | Comment Below
Related?Biocon to make world's first non-injection insulin pill September 10th, 2008 In their attempt to make the world's first non-injection insulin pill, Indian pharmaceutical giant Biocon has been successful in the human clinical trial. The company conducted its phase II trials on the revolutionary non-tablet-form insulin (codenamed IN-105) this year. Sleep apnea remains widely undiagnosed in obese diabeticsMay 22nd, 2009 WASHINGTON - Sleep apnea remains widely undiagnosed among obese individuals with type 2 diabetes, finds a new study. The researchers found that nearly 87 percent of participants reported symptoms, but were never diagnosed. AstraZeneca PLC to sell type 2 drug in Japan December 9th, 2008 AstraZeneca PLC and Bristol-Myers Squibb Co. announced plan to extend in Japan. Australian Study Provides Major Breakthrough In Diabetes TreatmentAugust 18th, 2008 In a major breakthrough in the medical science and research, the Australian researchers have developed a device to with a promise to make an end to diabetes and its related diseases like heart disease and other illnesses. The researchers have told that so far, there is no drug in the market to control the element fibrosis. China registers Cuban drug to treat diabetesMay 5th, 2009 BEIJING - The Chinese government has registered a Cuban drug that is used for treating acute diabetic patients, officials said. The Heberprot-B, a drug manufactured in Cuba, was introduced in Beijing Monday. AstraZeneca's Oral Drug Onglyza (Saxagliptin) Successful in Type 2 Diabetes Control, May Be Available Soon June 11th, 2008 AstraZeneca, the second largest drug maker in UK is all set to launch its newest product Saxagliptin for late stage diabetes. The drug is to be released in the brand name of Onglyza. Extended-Release Type 2 Diabetes Drug, ACTOplus met, Submitted for FDA Approval April 6th, 2006 ACTOplus met, a New Drug Application for an extended-release version of its type 2 diabetes drug would allow for once-daily dosing was submitted by Takeda Pharmaceutical Co.'s (4502.TO) U.S. arm to the Food and Drug Administration. R1583 Type 2 Diabetes (NIDDM) Drug Gets Strong RatingMay 30th, 2008 A drug having code number R 1583, a Swiss company's product, is going to mark a significant improvement in the history of medical Diabetes. The drug belongs to a new type group called GLP-1 analogues which aims in treating type 2 diabetes. Biocon unveils India’s first 24-hour diabetes drug
Get all the information and photos:: http://coringa.info/uncategorized/biocon-unveils-indias-first-24-hour-diabetes-drug
0 comments:
Post a Comment